As the 5-year survival rate of patients with TNBC is significantly lower than that of other breast cancers due to increased metastasis, utilizing a therapy such as αEGFR-E-P125A, which inhibits α5β1 integrin/FAK-mediated motility and tumor cell invasiveness is a promising therapeutic approach for patients with TNBC (56). Here, PTK2 is linked to breast carcinoma.